Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants

A Drug-drug Interaction Study to Evaluate the Impact of Multiple Subcutaneous Injections of ZT002 on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin and Digoxin in Overweight and Obese Participants

ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45.

The study consists of two cohorts. Each participant can only join one of the cohorts.

Cohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single dose of warfarin. Participants are screened within 2 weeks before study drug administration. In the first period, metformin is given twice daily for 3.5 days and warfarin is given as a single dose without ZT002. In the second period, metformin and warfarin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.

Cohort 2 evaluates the impact of ZT002 on the PK of single doses of rosuvastatin and digoxin. Participants are screened within 2 weeks before study drug administration. In the first period, rosuvastatin and digoxin are given as single doses without ZT002. In the second period, rosuvastatin and digoxin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.

Study Overview

• Status: Not yet recruiting
• Conditions: Overweight,Obesity
• Intervention / Treatment: Drug: ZT002 injection, metformin, warfarin; Drug: ZT002 injection, rosuvastatin, digoxin

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Pei Liu; Phone Number: +86-18810808386; Email: liu.pei@qlbiopharm.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • West China Second Hospital, Sichuan University
      • Contact: Qin Yu, Master

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;
• Male (body weight >60.0 kg) or female (body weight >55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg/m²(both inclusive);
• Considered to be generally healthy based on physical examination, and the results of vital signs, 12-lead electrocardiogram and clinical laboratory tests (hematology, urinalysis, chemistry, coagulation), as judged by the investigator.

Exclusion Criteria:

• Clinically significant diseases detected within 6 months before screening (including but not limited to neurological, psychiatric, cardiovascular, endocrine, gastrointestinal, respiratory, urinary, hematological, immunological diseases), judged by the investigator as possible to influence the study result or introduce safety risk to study drug administration;
• History of dysphagia or any gastrointestinal tract disease that affects drug absorption;
• Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;
• History of inspirational pneumonia within 5 years before screening;
• Medical history of hypoglycemia within 6 months before screening;
• History of acute or chronic pancreatitis;
• Cholelithiasis ≤ 1 cm, or history of cholecystitis or other symptomatic gallbladder disease, with the exception of cholecystectomy > 6 months prior to screening;
• History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2;
• Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol/L at screening;
• Aspartate aminotransferase ≥ 2 × upper limit of normal (ULN), Alanine aminotransferase ≥ 2 × ULN,
• Alkaline phosphatase total bilirubin ≥ 1.5 × ULN;
• Calcitonin above ULN at screening;
• Thyroid stimulating hormone (TSH) < 0.4 or >6.0 mIU/L;
• Use of hypoglycemic drugs (e.g. insulin, insulin secretagogues, thiazolidinedione, sodium-dependent glucose transporters 2 inhibitors [SGLT2i], dipeptidyl peptidase 4 inhibitor [DPP-4i], glucagon-like peptide-1 receptor agonist [GLP-1RA], metformin, α-glucosidase inhibitor) within 3 months before screening;
• Use of prescription drugs, over-the-counter drugs, dietary supplements, vitamins, or herbal medicines (excluding topical eye/nose drops and external use on the skin without systemic exposure risk) within 2 weeks before screening.

Exclusion criteria only applicable to Cohort 1:

• History that increases risk of bleeding, e.g. aneurysm, aortic dissection, cerebral vascular malformation, acute gastritis, gastric or duodenal ulcer; hemorrhoid bleeding within 1 month prior to screening;
• Hypersensitivity to metformin or warfarin;
• Prothrombin time (PT), international normalized ratio (INR) or activated partial thromboplastin time (APTT) above ULN and judged as clinically significant by investigator;
• Platelet < 100x109/L;
• Ventricular rate < 50 or > 100 bpm, second or third degree of atrioventricular block, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) > 450 ms, or other abnormal electrocardiogram of clinical significance.

Exclusion criteria only applicable to Cohort 2:

• History of unexplained myalgia or myasthenia, or diagnosed with rhabdomyolysis;
• Hypersensitivity to rosuvastatin or digoxin;
• Unexplained creatine kinase above ULN;
• Serum potassium out of reference range;
• Ventricular rate < 55 or > 100 bpm, atrial fibrillation, atrioventricular block of any degree, preexcitation syndrome, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) > 450 ms, or other abnormal electrocardiogram of clinical significance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: cohort1; ZT002 injection, metformin, warfarin	Drug: ZT002 injection, metformin, warfarin; Drug: metformin Participants will receive metformin twice daily for 3.5 days in both periods Drug: warfarin Participants will receive a single dose of warfarin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period
Experimental: cohort2; ZT002 injection, rosuvastatin, digoxin	Drug: ZT002 injection, rosuvastatin, digoxin; Drug: rosuvastatin Participants will receive a single dose of rosuvastatin in both periods Drug: digoxin Participants will receive a single dose of digoxin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the concentration-time curve of metformin within dosing interval (12 hours) at steady state	From Day 4 to Day 5, from Day 112 to Day 113
Area under the concentration-time curve of S-warfarin from time zero to infinity after single-dose administration	From Day 6 to Day 13, from Day 126 to Day 133
Area under the concentration-time curve of R-warfarin from time zero to infinity after single-dose administration	From Day 6 to Day 13, from Day 126 to Day 133
Area under the concentration-time curve of rosuvastatin from time zero to infinity after single-dose administration	From Day 1 to Day 5, from Day 111 to Day 115
Area under the concentration-time curve of digoxin from time zero to infinity after single-dose administration	From Day 5 to Day 12, from Day 125 to Day 132

Secondary Outcome Measures

Outcome Measure	Time Frame
Maximal observed concentration of metformin at steady state	From Day 4 to Day 5, from Day 112 to Day 113
Maximal observed concentration of S-warfarin after single-dose administration	From Day 6 to Day 13, from Day 126 to Day 133
Maximal observed concentration of R-warfarin after single-dose administration	From Day 6 to Day 13, from Day 126 to Day 133
Maximal observed concentration of rosuvastatin after single-dose administration	From Day 1 to Day 5, from Day 111 to Day 115
Maximal observed concentration of digoxin after single-dose administration	From Day 5 to Day 12, from Day 125 to Day 132
Area under the INR-time curve after single-dose warfarin administration	From Day 6 to Day 13, from Day 126 to Day 133
Maximal INR after single-dose warfarin administration	From Day 6 to Day 13, from Day 126 to Day 133
Percentage change in body weight	Day 13 and Day 133 in Cohort 1, Day 12 and Day 132 in Cohort 2
Proportion of participants with positive anti-drug antibody against ZT002	From Day 13 to Day 167 in Cohort 1, from Day 12 to Day 166 in Cohort 2
Proportion of participants with treatment-emergent adverse events	From baseline to Day 167 in Cohort 1, from baseline to Day 166 in Cohort 2
Proportion of participants with serious adverse events	From baseline to Day 167 in Cohort 1, from baseline to Day 166 in Cohort 2

Collaborators and Investigators

• Sponsor: Beijing QL Biopharmaceutical Co.,Ltd
• Investigators: Principal Investigator: Qin Yu, Master, West China Second University Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): May 20, 2026
• Primary Completion (Estimated): December 5, 2026
• Study Completion (Estimated): March 26, 2027

Study Registration Dates

• First Submitted: April 20, 2026
• First Submitted That Met QC Criteria: April 20, 2026
• First Posted (Actual): April 24, 2026

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans; Hydrocarbons; Carbohydrates; Polycyclic Compounds; Glycosides; Amides; Pyrimidines; Steroids; Fused-Ring Compounds; Hydrocarbons, Halogenated; Biguanides; Guanidines; Amidines; Sulfonamides; Sulfones; Coumarins; Benzopyrans; Fluorobenzenes; Hydrocarbons, Fluorinated; Digitalis Glycosides; Cardenolides; Cardiac Glycosides; Cardanolides; 4-Hydroxycoumarins; Rosuvastatin Calcium; Digoxin; Metformin; Warfarin
• Other Study ID Numbers: BJQL-ZT002-1007

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No